WHO ICTRP trial
Safety of Yeast Extract containing NMN
JPRN-jRCTs041190080 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs041190080 |
|---|---|
| Public title | Safety of Yeast Extract containing NMN |
| Scientific title | Safety assessment of the Yeast Extract containing nicotinamide mononucleotide (NMN) |
| Primary sponsor | Nakagawa Takashi |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 1 |
| Conditions | Not applicable |
| Interventions | Oral administration of Yeast extract containing NMN or placebo (Dextran) at 2.8 g/day (14 tablets twice at morning and evening) for 12 weeks.NMN dosages in Yeast extract containing NMN and placebo are 250 mg and 0 mg, respectively. |
| Registration date | Nov 20, 2019 |
| Target size | 33 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: